Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin

Journal of Family Practice

Volumn 45, Issue 4, 1997, Pages 295-318

  Zimmerman, Richard Kent ^a   Ruben, Frederick L ^a   Ahwesh, Ellen R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B vaccines; Hepatitis B virus; Immunization; Liver diseases; Physicians, family; Preventive services; Public health; Sexually transmitted diseases

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; DRUG EFFICACY; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PREVALENCE; REVIEW; UNITED STATES; VACCINE PRODUCTION;

ADOLESCENT; ADULT; CHILD; FAMILY PRACTICE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFANT; UNITED STATES;

EID: 0030867227     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Centers for Disease Control and Prevention. Hepatitis B virus infection: a comprehensive immunization strategy to eliminate transmission in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) [draft]. MMWR 1997. In press.
2. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med 1994; 10(suppl):45-55.
3. Centers for Disease Control and Prevention. National Immunization Program. Epidemiology and Prevention of Vaccine-Preventable Diseases. 3rd ed. Atlanta, Ga: Centers for Disease Control and Prevention, 1996.
4. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990; 263:1218-22.
5. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976; 32:572-4.
6. Franks AL, Berg CJ, Kane MA, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989; 321:1301-5.
7. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992; 89:269-73.
8. Craxi A, Tine F, Vinci M, et al. Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol 1991; 134:641-50.
9. Hayashi J, Kashiwagi S, Nomura H, Kajiyama W, Ikematsu H. Hepatitis B virus transmission in nursery schools. Am J Epidemiol 1987; 125:492-8.
10. Centers for Disease Control. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989; 38(S-6):1-37.
11. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11(2):84-92.
12. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-90.
13. Centers for Disease Control. Public Health Service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991; 40(RR-4):1-17.
14. Centers for Disease Control and Prevention. Sensitivity of the test for antibody to hepatitis B surface antigen, United States. MMWR 1993; 42(36):707-10.
15. Dienstag JL, Isselbacher KJ. Acute hepatitis. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine. 13th ed. New York, NY: McGraw-Hill Inc, 1994.
16. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York, NY: Churchill Livingstone, 1995:1406-39.
17. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295-301.
18. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human (alpha)-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-25.
19. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1994; 333:1657-61.
20. DiBisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference: Hepatocellular carcinoma. Ann Intern Med 1988; 108:390-401.
21. Centers for Disease Control. Summary of a workshop on screening for hepatocellular carcinoma. MMWR 1990; 39:619-21.
22. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432-8.
23. Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994; 9:361-5.
24. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 21:708-12.
25. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J 1996; 15:590-6.
26. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E. Response to hepatitis B vaccination: a randomized trial comparing the immunogenicity of Engerix-B™ and Recombivax-HB™ [abstract H18]. Presented at the 34th ICAAC, October 4-7, 1994, Orlando, Florida.
27. Shaw FE Jr, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years. Am J Epidemiol 1988; 127:337-52.
28. Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press, 1994.
29. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262:1201-5.
30. Summers PR, Biswas MK, Pastorek JG 2d, Pernoll ML, Smith LG, Bean BE. The pregnant hepatitis B carrier: evidence favoring comprehensive antepartum screening. Obstet Gynecol 1987; 69:701-4.
31. Kumar ML, Dawson NV, McCullough AJ, et al. Should all pregnant women be screened for hepatitis B? Ann Intern Med 1987; 107:273-7.
32. Centers for Disease Control. Changing patterns of groups at high risk for hepatitis B in the United States. MMWR 1988; 37:429-33.
33. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993; 118:298-306.
34. Centers for Disease Control and Prevention. Recommended childhood immunization schedule-United States, 1997. MMWR 1997; 46:35-40.
35. Margolis HS, Coleman PG, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. JAMA 1995; 274:1201-8.
36. Centers for Disease Control and Prevention. FDA approval for infants of a Haemophilus influenzas type b conjugate and heptatitis B (recombinant) combined vaccine. MMWR 1997; 46(5): 107-9.
37. Centers for Disease Control and Prevention. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(RR-13):1-16.
38. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore, Md: Williams & Wilkins, 1996.
39. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985; 76:713-18.
40. Shapiro CN. Epidemiology of hepatitis B. Pediatr Infect Dis J 1993; 12:433-7.
41. Sehgal A, Gupta I, Sehgal R, Ganguly NK. Hepatitis B vaccine alone or in combination with anti-HBs immunoglobulin in the perinatal prophylaxis of babies born to HBsAg carrier mothers. Acta Virol 1992; 36:359-66.
42. Hsu H-M, Chen D-S, Chuang C-H, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988; 260:2231-5.
43. West DJ, Margolis HS. Prevention of hepatitis B virus infection in the United States: a pediatric perspective. Pediatr Infect Dis J 1992; 11:866-74.
44. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices: programmatic strategies to increase vaccination rates - assessment and feedback of provider-based vaccination coverage information. MMWR 1996; 45(10):219-20.
45. Zimmerman RK, Barker WH, Strikes RA, et al. Developing curricula to promote preventive medicine skills: the Teaching Immunization for Medical Education (TIME) project. JAMA 1997; 278:705-11.